Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.

US-listed fertility treatment provider OvaScience has agreed to merge with Millendo Therapeutics, a US-based endocrine disease drug spinout of University of Michigan. The unified company will take Millendo’s name and OvaScience’s stock listing on the Nasdaq Capital Market. Millendo’s investors will own 80% of the combined company and Ovascience shareholders 20%. The all-stock deal will…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.